“Twenty randomised controlled trials (RCTs) comprising 15 782 participants met inclusion criteria. Lean mass constituted 25%-39% of total weight lost with incretin agonists: semaglutide (35.2% [95% CI: 31.5-38.9]), tirzepatide (25.4% [22.8-28.0]) and liraglutide (26.8% [23.1-30.5]). Lifestyle interventions showed comparable proportional lean mass loss (26.2% [24.1-28.3]; p = 0.42 for comparison), while lifestyle plus resistance training demonstrated the most favourable profile (17.5% [14.2-20.8]). Heterogeneity was moderate (I2 = 68%). No publication bias was detected (Egger’s test p = 0.23).”
National Center for Biotechnology Information | Health & Medical Care
